The primary role of Orilissa (Elagolix Sodium) is the focused symptomatic management of endometriosis-associated pain in adult premenopausal women. This medication is commonly used for the management of moderate to severe pain associated with the condition.

Relief from Chronic and Cyclical Pelvic Pain

This therapeutic domain encompasses the core pain symptoms that characterize endometriosis, specifically addressing dysmenorrhea (painful menstrual periods), non-menstrual pelvic pain (persistent pain between periods), and dyspareunia (pain during sexual intercourse). The treatment may assist with managing the overall intensity of these challenging symptoms, providing support that contributes to easing the overall symptom load of the disease. This is considered relevant when symptoms become temporarily overwhelming or have not been adequately controlled by initial, conventional therapies.

“The medication is used across domains where additional symptomatic support is needed to address pain clusters that may become intense or disruptive.”

Management of Functional Pain and Impairment

For patients whose pain has not been adequately controlled by initial therapies, this option offers symptomatic relief that may help patients cope more steadily with symptom fluctuations and supports improved comfort and stability during routine activities.

---

Quick Fact: Relief for Endometriosis-Associated Pain Orilissa is relevant for conditions where symptoms present with localized discomfort and functional stability becomes affected, helping patients manage moderate to severe pain symptoms.

Official Eligibility Profile for Orilissa (Elagolix)

Orilissa is regulated for use only within specific population boundaries as defined by governmental health authorities. The medicine is primarily intended for adult premenopausal women with moderate to severe pain associated with endometriosis.

---

Populations Who Must Not Use Orilissa (Contraindications)

Use is absolutely prohibited (contraindicated) for women who are pregnant or suspected of being pregnant, due to the potential risk of early pregnancy loss. It is also contraindicated for patients with known osteoporosis or severe hepatic impairment (Child-Pugh Class C). Additionally, those with a known hypersensitivity to elagolix or who are taking strong OATP1B1 inhibitor medications must not use Orilissa.

Eligibility Restrictions

Domain	Regulatory Status
Age Group	Not established for the pediatric population (under 18 years).
Lactation	Use is not recommended while breastfeeding.
Duration	Restricted to a maximum of 6 months (high dose) or 24 months (low dose).
Hepatic Function	Restricted to the lower dose and 6-month limit in moderate impairment.
Contraception	Requires use of effective non-hormonal contraception during treatment and for 28 days following discontinuation.

Interactions with other medicines and products

Interaction scope

Medicinal product categories with documented interactions include Strong Organic Anion Transporting Polypeptide (OATP) 1B1 Inhibitors (such as Cyclosporine), Strong CYP3A Inhibitors (like Ketoconazole), and Strong CYP3A Inducers (like Rifampin or St. John's Wort). Elagolix is a substrate for OATP1B1 and the P-glycoprotein (P-gp) transporter. As a perpetrator, Elagolix is documented to inhibit OATP1B1 and P-gp, potentially increasing the plasma concentrations of co-administered substrates such as Rosuvastatin and Digoxin.

Interaction-related restrictions

Co-administration is contraindicated with all Strong OATP1B1 Inhibitors due to the significant risk of increased Elagolix exposure. Co-administration with Strong CYP3A Inducers is not recommended because this typically decreases Elagolix levels. Use with Strong CYP3A Inhibitors has time limitations: the 150 mg once daily dose is restricted to six months of concomitant use, and the 200 mg twice daily dose is not recommended for more than one month. Estrogen-Containing Contraceptives are also not recommended with the 200 mg twice daily dose, as this combination increases estrogen exposure and can reduce Orilissa's efficacy. The 200 mg twice daily dose is also not recommended in patients with moderate hepatic impairment due to increased exposure risks.

Connection to the overall interaction profile

Official regulatory documents define the interaction structure primarily through two types of pharmacokinetic interference: OATP1B1 transporter inhibition, which results in absolute prohibitions, and CYP3A enzyme modulation, which establishes strict dose- and duration-dependent constraints. The profile further mandates specific warnings related to Orilissa's role as a transporter inhibitor affecting other co-administered medications, such as P-gp and OATP1B1 substrates.

Molecular Blockade of the Pituitary GnRH Receptor

This mechanism begins with Elagolix acting as a competitive antagonist at the Gonadotropin-Releasing Hormone Receptor ( GnRH-R), located in the anterior pituitary gland. The molecule binds to this receptor and immediately prevents the body’s endogenous GnRH from initiating the signaling sequence. The antagonist action provides immediate inhibition of the receptor, avoiding the initial stimulatory phase characteristic of GnRH agonists.

---

Dose-Dependent Suppression of the HPG Axis

The initial blockade disrupts the entire Hypothalamic-Pituitary-Gonadal ( HPG) axis cascade. The pituitary, receiving no signal, reduces the secretion of downstream hormones Luteinizing Hormone ( LH) and Follicle-Stimulating Hormone ( FSH). This systemic gonadotropin suppression is dose-dependent, meaning the degree of hormonal change is controlled by the concentration of the drug.

---

Achieving Controlled Estradiol ( E2) Modulation

The reduction of LH and FSH leads to a proportional decrease in the ovarian production of sex hormones, primarily Estradiol ( E2). The resulting physiological effect is a state of controlled hypoestrogenism, which alters the activity of estrogen-dependent tissue. This mechanism establishes a changed hormonal environment for estrogen-dependent tissue.

How Orilissa (Elagolix Sodium) is Used

Orilissa is supplied as a film-coated tablet and is administered orally, representing the only approved route of intake. The medicine is taken daily and continuously, rather than in a cyclical pattern. Administration guidelines define the specific dose based on the maximum allowed duration of use.

---

Labeled Dosing Regimens and Duration Limits

The medicine is available in two distinct dosage strengths, 150 mg and 200 mg of Elagolix. The choice of regimen dictates the maximum time limit for continuous use:

Regimen	Frequency	Maximum Duration
150 mg	Once daily (QD)	24 months
200 mg	Twice daily (BID)	6 months

---

Administration Conditions and Adjustments

The tablet may be administered with or without food and should be taken at approximately the same time each day to maintain a steady schedule. Treatment should be initiated within seven days of the onset of menses.

Specific dosage modifications are required for certain populations. For adult patients with moderate hepatic impairment (Child-Pugh B), the dose is restricted to 150 mg once daily, and the duration is limited to 6 months. No dosage adjustment is required for patients with any degree of renal impairment.

Evidence for Management of Endometriosis-Associated Pain

The research base for Orilissa was studied for endometriosis-associated pain, a condition where symptoms may vary in intensity. The core evidence comes from multiple Pivotal Phase 3 Randomized Controlled Clinical Trials that compared the medicine to a placebo. The core outcomes monitored were dysmenorrhea (painful periods) and non-menstrual pelvic pain (persistent pain between periods).

Researchers defined success based on meeting a dual metric of a measured change in pain scores without increasing rescue painkiller use. Studies reported that a proportion of the study populations met these specific research criteria for change in pain scores. Research also monitored scores for dyspareunia and various outcomes reflecting daily functioning or activity level.

Research Focusing on Specific Pain Types

Research examined temporary physiological imbalance related to endometriosis symptoms by studying how symptoms evolved in trials focusing on three distinct pain types. For both dysmenorrhea and non-menstrual pelvic pain, studies report how symptoms evolved in the observed populations, documenting measured changes in pain scores over the study intervals.

Long-Term Studies and Follow-Up Data

The pivotal clinical trials initially focused on research exploring short-term symptom changes over periods of three to six months. Open-label extension studies were later conducted, allowing researchers to observe responses over defined time intervals of up to 12 months. This continued research was observed in these populations to help contextualize how patients reported their experience when treated for an extended period. However, the long-term effects are not fully established beyond these 12-month studies.

Evidence in Study Populations

The evidence supporting the research profile for Orilissa is based on study results that apply only to the populations studied. The core clinical program was evaluated in a specific and uniform group: adult premenopausal women diagnosed with endometriosis who experienced moderate to severe associated pain.

What Remains Uncertain in the Research

One area of research uncertainty noted in regulatory documentation relates to the long-term profile of Bone Mineral Density (BMD), which studies monitored over short-term periods. Research exploring the long-term impact on BMD beyond the study duration is not fully established, and there is limited information regarding the impact of continued treatment in this area.

Furthermore, the pivotal research primarily compared the medicine to a placebo, meaning head-to-head research comparing measured outcomes to other active treatments remains limited in the regulatory documentation. This means that while studies contribute to the broader evidence landscape, comparative evidence against other active treatments remains limited.

Common questions about Orilissa (FAQ)

---

Q: How is Orilissa different from birth control pills used for endometriosis?

Orilissa is a Gonadotropin-Releasing Hormone (GnRH) receptor antagonist that works by reducing the body’s production of estrogen.

In contrast, most birth control pills contain synthetic estrogen and/or progestin. Official prescribing information states the requirement for non-hormonal contraception with Orilissa because using estrogen-containing contraceptives may reduce the medicine's overall effectiveness.

---

Q: Can Orilissa completely cure endometriosis?

According to official regulatory documents, Orilissa is approved for the management of moderate to severe pain associated with endometriosis.

It is designed to help reduce associated pain symptoms during the treatment period, but it is not described as a cure for the condition itself.

---

Q: How quickly should a person expect to feel a difference after starting Orilissa?

Clinical studies indicate that a statistically significant reduction in pain—specifically for painful periods (dysmenorrhea) and non-menstrual pelvic pain—was generally observed at three months of treatment compared to placebo.

While the drug acts immediately in the body, the observable reduction in symptoms may take longer than the immediate action of the drug in the body.

---

Q: What is the most serious side effect reported with Orilissa?

The official label highlights two major safety concerns. One is a dose- and duration-dependent decrease in Bone Mineral Density (BMD), which is the density of the bone.

The other concern is the risk of suicidal ideation (thoughts of suicide), suicidal behavior, and the worsening of existing mood disorders.

---

Q: Does Orilissa affect weight gain or loss?

Clinical trial data indicated that weight gain was reported as a less common side effect in some women taking Orilissa.

No other significant weight changes are emphasized in the primary safety information found in official documents.

---

Q: Are there any common over-the-counter medications that interact with Orilissa?

Official drug information notes an interaction with certain types of enzyme inducers, which includes the commonly available herbal supplement St. John’s Wort.

Official labeling states that co-administration with St. John’s Wort is not recommended because it can decrease the concentration of Orilissa in the body, which may reduce its effectiveness.

---

Q: Can men take Orilissa for any condition?

According to regulatory documentation, Orilissa is indicated for the management of moderate to severe pain associated with endometriosis in women.

The core clinical research studies focused exclusively on this population.

---

Q: Can Orilissa still be effective if I have severe or deep endometriosis?

Official information states that Orilissa is approved to manage pain in adult women with moderate to severe pain associated with endometriosis.

The medicine's efficacy was established in studies that included patients with moderate to severe pain symptoms.

---

Q: If I miss a dose of Orilissa, what does the official information say to do?

If a dose is missed, official instructions state that the tablet should be taken as soon as it is remembered on the same day.

Official guidelines state that the patient should return to their regular schedule the next day and must not take more than the prescribed number of tablets per day.

---

Q: What happens when a person stops taking Orilissa?

When treatment is stopped, there is a possibility that endometriosis pain symptoms may recur.

For those who experienced bone loss during treatment, the bone mineral density (BMD) may begin to improve, but official information indicates that it may not recover completely.

---

Q: Is bone density loss a temporary or permanent risk with Orilissa?

Regulatory documents state that the decrease in bone mineral density (BMD) associated with the medicine may not be completely reversible after discontinuing treatment.

The long-term impact on bone health beyond the duration of clinical studies is not fully established.

---

Q: Are certain types of headaches associated with taking Orilissa?

Headache is listed in official documents as one of the most frequently reported adverse reactions, classified as very common.

However, the summary sections of the regulatory label do not provide specific details or classifications about different types of headaches (such as tension or migraine) experienced in the clinical trials.

---

Q: Why is it important to have a bone density scan before starting Orilissa?

Orilissa can cause a further decrease in bone mineral density (BMD) and is officially contraindicated (prohibited) in patients with known osteoporosis.

Due to this, official labels discuss the need to consider BMD assessment for patients who have risk factors for bone loss or a history of bone fractures.

---

Q: Is Orilissa used to treat chronic pelvic pain from sources other than endometriosis?

Official regulatory indications specify that Orilissa is intended for the management of moderate to severe pain associated with endometriosis in adult women.

Its approved use is limited to the pain caused by this specific condition.

---

Q: Does Orilissa affect cholesterol levels?

Clinical trial data showed that the medicine can be associated with changes in blood fat levels. Studies documented significant increases in both total cholesterol and LDL cholesterol levels compared with placebo, especially when the higher dose was used.

---

Q: Why is the mechanism of action of Orilissa described as reversible?

Orilissa is classified as a Gonadotropin-Releasing Hormone (GnRH) antagonist, meaning it acts as a direct blocker.

This antagonist action allows for immediate and dose-dependent control over the hormonal axis without causing the initial stimulatory surge that characterizes older GnRH agonist medicines.

---

Q: Is it true that Orilissa can change results on laboratory tests?

The official safety profile notes that the drug is associated with potential elevations in hepatic transaminase levels, which are measured through laboratory tests to monitor liver function.

This indicates the medicine can influence the results of certain clinical lab work.

How to Store and Dispose of Orilissa (elagolix) Tablets

Storage Conditions and Requirements

Orilissa tablets must be stored at a controlled room temperature, specifically between 36 F and 86 F (2 C and 30 C). The medication must be kept away from excess heat and moisture, which prohibits storing it in the bathroom. It is required to keep the tablets in the original container, which must remain tightly closed, and the product must be kept from freezing. Orilissa and all other medicines must be stored out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Orilissa must not be flushed down the toilet. For proper disposal, the official instruction is to utilize community drug take-back programs when they are available. If a take-back program is not accessible, the product must be thrown away following specific regulatory guidance for non-flushable household disposal.